NeoGenomics Launches RaDaR ST for HPV-Negative Head and Neck Cancer MRD Detection (neogenomics.com)

• Tumor-informed MRD test for HPV-negative HNSCC
• 91.3% clinical sensitivity; median 119-day lead time
• Detects ctDNA at 1 ppm; complements PanTracer CGP

"NeoGenomics launched RaDaR ST, a tumor-informed MRD test for HPV-negative HNSCC, using ctDNA analysis. The test achieves 91.3% clinical sensitivity for relapse detection with a median lead time of 119 days before clinical confirmation, based on the LIONESS study. It detects down to 1 ppm ctDNA. RaDaR ST complements NeoGenomics' PanTracer profiling and targets earlier intervention across the care continuum."